LD

BORED SLOT Secures $10M from PLUTUS VC and LD Capital, Integrating BAYC NFTs to Revolutionize Social Crypto Slots Gaming

Retrieved on: 
Wednesday, April 10, 2024
Sale, Ecosystem, Partnership, Non-fungible token, Bored Ape, SPC, BAYC, LD

This strategic partnership aims to redefine social slots gaming by harnessing the power of the iconic Bored Ape Yacht Club (BAYC) NFTs.

Key Points: 
  • This strategic partnership aims to redefine social slots gaming by harnessing the power of the iconic Bored Ape Yacht Club (BAYC) NFTs.
  • BORED SLOT, a web3 slots gaming project, will use the funding to launch a slot platform that will provide digital token mining by simply playing slots on the platform.
  • Spin City, a trailblazing newcomer in digital entertainment and blockchain applications, is dedicated to redefining gaming through blockchain technology.
  • "BORED SLOT has the potential to be transformative and we are immensely excited about its prospects," states Calvin Ng of PLUTUS VC.

National Association for Veteran Rights Condemns Maine Legislative Action to Deny Veteran Choice – Urges Governor to Veto

Retrieved on: 
Wednesday, April 10, 2024
Public Policy, Government, State, Local, Defense, Other Policy Issues, Other Defense, Veterans, Veterans' affairs, LD, Legislation, Letter, National Association

The National Association for Veteran Rights (NAVR) opposes the recent passage of Maine Legislative Document 2259 (ME LD 2259), as it strips Maine Veterans of the right to use NAVR member companies to help them secure their disability benefits, and is urging the Governor to veto the unconstitutional legislation.

Key Points: 
  • The National Association for Veteran Rights (NAVR) opposes the recent passage of Maine Legislative Document 2259 (ME LD 2259), as it strips Maine Veterans of the right to use NAVR member companies to help them secure their disability benefits, and is urging the Governor to veto the unconstitutional legislation.
  • The bill, if signed by the Governor, fails to address critical issues such as providing additional oversight and protections for Veterans while preserving their constitutional rights and ensuring access to diverse and effective solutions.
  • NAVR President O’Rourke emphasized the importance of protecting Veterans’ rights to petition their government, citing similar legislation facing legal challenges on First Amendment grounds in other states.
  • The National Association for Veteran Rights (NAVR) is a national trade association committed to promoting ethical and transparent business practices among companies engaging with the service-disabled Veteran community.

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress

Retrieved on: 
Thursday, March 28, 2024
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, The Lancet, Research, Graft-versus-host disease, LD, ASH, International Society, Partnership, Central nervous system, ATRA, Epstein–Barr virus, Patient, Follicular lymphoma, CNS, Biomarker, PTLD, Cancer, Lymphoproliferative disorders, SLE, EBV, NHL, Lymphoma, Mantle cell lymphoma, Investment, ATM, Safety, Pharmacokinetics, Depreciation, File, Workforce, Cell, FDA, BLA, Lupus nephritis, CD19, Food, Autoimmune disease, Pharmaceutical industry

“We are expanding Atara’s proven EBV T-cell platform into allogeneic CAR T therapy for both oncology and autoimmune disease,” said Pascal Touchon, President and Chief Executive Officer of Atara.

Key Points: 
  • “We are expanding Atara’s proven EBV T-cell platform into allogeneic CAR T therapy for both oncology and autoimmune disease,” said Pascal Touchon, President and Chief Executive Officer of Atara.
  • “This includes strong momentum for our lead CAR T program, ATA3219, which is positioned to deliver near-term clinical data for both non-Hodgkin’s lymphoma and lupus nephritis.
  • Subjects will receive lymphodepletion (LD) treatment followed by ATA3219 at a dose of 40, 80, or 160 x 106 CAR+ T cells.
  • Subjects will receive LD treatment followed by ATA3219 at a dose of 40, 80, 240, or 480 x 106 CAR+ T cells.

Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial Results

Retrieved on: 
Tuesday, March 19, 2024
Mental Health, Health, Neurology, Clinical Trials, Pharmaceutical, Biotechnology, Research, Pharmacology, LD, Survival, Serum, ALS, Science, PD, Houston Methodist Hospital, Patient, Regulatory affairs, Granulocyte-macrophage colony-stimulating factor, FD, GM-CSF, Nebraska Medicine, COYA, University, IPO, Senior, Society, IND, Commerce, Viral disease, Therapy, Frontotemporal dementia, FDA, FTD, Pharmaceutical industry

Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a corporate update and announces its financial results for the year ended December 31, 2023.

Key Points: 
  • Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a corporate update and announces its financial results for the year ended December 31, 2023.
  • COYA 302 is Coya’s combination of its proprietary LD IL-2 formulation with the immunomodulatory drug CTLA4-Ig.
  • “We believe that we have under-promised and over-delivered in executing on numerous deliverables in 2023 that have brought value to Coya,” commented Howard Berman, Ph.D., Chief Executive Officer of Coya.
  • Net loss was $8.0 million for the year ended December 31, 2023, compared to net loss of $12.2 million for the year ended December 31, 2022.

Coya Therapeutics Presents ALS Biomarker Data at Society of Neuroimmune Pharmacology Conference

Retrieved on: 
Tuesday, March 12, 2024
Health, General Health, Research, Pharmaceutical, Science, Biotechnology, Diagnosis, Pharmacology, LD, Conference, Survival, Serum, Coya, Disease, ALS, Associate, Patient, Biomarker, COYA, ROS, Death, Reactive oxygen species, Society, Therapy, Patent, FDA, Oxidative stress

The data presented highlights the strong predictive value of levels of an oxidative stress biomarker (4-HNE) with the rate of disease progression and survival in 50 ALS patients from a longitudinal patient registry cohort.

Key Points: 
  • The data presented highlights the strong predictive value of levels of an oxidative stress biomarker (4-HNE) with the rate of disease progression and survival in 50 ALS patients from a longitudinal patient registry cohort.
  • In a proof-of-concept study in patients with ALS, the combination of low dose interleukin-2 (LD IL-2) and CTLA-4 Ig appeared to lower 4-HNE and other proinflammatory biomarker levels.
  • Furthermore, Coya has filed patent applications relating to the use of the biomarker in ALS.
  • Data was collected from a previously established biobank at Houston Methodist to monitor and track ALS patient outcomes with biomarkers.

Academy of Nutrition and Dietetics Promotes Tool to Help Diagnose Malnutrition in Hospitalized Adults

Retrieved on: 
Thursday, March 7, 2024
Systematic review, Malnutrition, CNAME record, Nutrition, RDN, Dietitian, LD, Research, Education, American Journal, Quality of life, Weight loss, Content validity, Ellen Steiber, Government, Food, Health, Enteral administration, Society, University, Death, Route of administration, Energy, Meta-analysis, Patient, Journal, Mortality, Nursing

Many of these patients went undiagnosed because health care providers had no universally accepted tool to check, until now.

Key Points: 
  • Many of these patients went undiagnosed because health care providers had no universally accepted tool to check, until now.
  • A malnutrition tool, referred to as AAIM, can help registered dietitian nutritionists (RDNs) accurately diagnose malnutrition, according to two scientific papers from the Academy of Nutrition and Dietetics.
  • Armed with this tool and the accurate assessment of malnutrition, RDNs can provide medical nutrition therapy to improve patient outcomes and reduce health care costs.
  • Details about the AAIM tool can be found in the paper Predictive validity of the Academy of Nutrition and Dietetics/American Society for Parenteral and Enteral Nutrition indicators (AAIM) to diagnose malnutrition tool in hospitalized adults: a cohort study , now in press in The American Journal of Clinical Nutrition.

Global and China Autonomous Driving Map Industry Report 2024: How are Players Responding to the Development of New-Generation Autonomous Driving Maps - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 7, 2024
Software, Mobile, Wireless, Internet, General Automotive, Technology, Autonomous Driving, Vehicles, Automotive, Artificial Intelligence, Satellite, Automotive Manufacturing, Other Automotive, Manufacturing, Cloud, Classification, Algorithm, MAP, Ministry, Crowdsourcing, LD, Limited partnership, HD, ADAS, Original equipment manufacturer, NOA, NIO, Nature, Build automation, NGP, Natural Resources, ODD, Lead, Baidu Maps, Human, Baidu, City, Tencent, NPN, Map, GAC, Satellite navigation device

Autonomous Driving Map Industry Report, 2024 highlights the following:

Key Points: 
  • Autonomous Driving Map Industry Report, 2024 highlights the following:
    Autonomous driving map (formulation of policies, regulations, standards, etc.
  • );
    Application scenarios of intelligent driving map (high-speed autonomous driving of passenger cars, low-speed parking, autonomous human carrying, autonomous object carrying, etc.
  • 1 Status Quo of Policies, Standards and Regulations Concerning Autonomous Driving Map
    2.2 Classification of Autonomous Driving Maps: Navigation Map (SD Map)
    2.3 Classification of Autonomous Driving Maps: ADAS Map (SD Pro MAP)
    2.4 Classification of Autonomous Driving Maps: HD Map
    2.5 How Do Conventional Map Providers Make Layout Driven by Urban NOA?
  • 4.3 Intelligent Driving Map Application in Sub-scenarios: Low-speed Parking of Passenger Cars
    4.4 Intelligent Driving Map Application in Sub-scenarios: Autonomous Object Carrying
    4.5 Intelligent Driving Map Application in Sub-scenarios: Autonomous Human Carrying

Amneal Enters into Exclusive European Licensing Agreement with Zambon Biotech for IPX203

Retrieved on: 
Tuesday, February 27, 2024
Health, Other Health, General Health, Research, Science, Pharmaceutical, Biotechnology, Knight Therapeutics, PD, Zambon, LD, Food, European, Patient, Family, Medication, Neurology, Pharmaceutical industry

Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”) today announced that it has entered into an exclusive licensing agreement with Zambon Biotech SA, part of the Zambon group (“Zambon”), for IPX203 in the European Union, United Kingdom, and Switzerland.

Key Points: 
  • Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”) today announced that it has entered into an exclusive licensing agreement with Zambon Biotech SA, part of the Zambon group (“Zambon”), for IPX203 in the European Union, United Kingdom, and Switzerland.
  • Zambon will seek regulatory approval and commercialize IPX203 in Europe.
  • Today’s announcement of a licensing agreement with a European partner is part of Amneal’s broader strategy to bring IPX203 to Parkinson’s patients around the world.
  • Earlier this year, Amneal also signed a license agreement with Knight Therapeutics Inc. granting exclusive rights to seek regulatory approval and commercialize IPX203 in Canada and Latin America.

Coya Therapeutics Issues Letter to Stockholders Highlighting Expansion of COYA 302 into Alzheimer’s Disease and Coya’s Pathway to a “Pipeline in a Product”

Retrieved on: 
Wednesday, February 21, 2024
Mental Health, Health, Neurology, Clinical Trials, Pharmaceutical, Biotechnology, Cancer, Coya, CD4, PD, Immune system, Houston Methodist Hospital, Frontotemporal dementia, Research, LD, Inflammation, Neuroinflammation, COYA, Animal, Letter, FTD, GM-CSF, Safety, University, Biomarker, Therapy, Patient, Survival, Oxidative stress, IND, Protein aggregation, Partnership, Pharmaceutical industry

Today, we announce that we are further expanding the pipeline for COYA 302, adding Alzheimer’s disease (AD) to its growing list of indications expected to be validated in the clinic.

Key Points: 
  • Today, we announce that we are further expanding the pipeline for COYA 302, adding Alzheimer’s disease (AD) to its growing list of indications expected to be validated in the clinic.
  • Beyond COYA 302, our therapeutic platform includes additional drug product combinations using COYA 301 (our proprietary LD IL-2) as their backbone.
  • 2 investigator-initiated trial with COYA 301 in AD that we expect will support the development of COYA 302 in that same indication.
  • I look forward to providing investors with additional periodic updates on our research, clinical, corporate, and commercial progress.

Global and China Autonomous Driving Map Industry Report 2024 Featuring 14 Chinese and Foreign Map Providers and 4 HD Map Technology Companies

Retrieved on: 
Tuesday, March 5, 2024
Cloud, Classification, Algorithm, MAP, Ministry, Crowdsourcing, LD, Limited partnership, HD, ADAS, Original equipment manufacturer, NOA, NIO, Nature, Build automation, NGP, Natural Resources, ODD, Lead, Baidu Maps, Human, Baidu, City, Tencent, NPN, Map, GAC, Satellite navigation device

DUBLIN, March 5, 2024 /PRNewswire/ -- The "Autonomous Driving Map Industry Report, 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, March 5, 2024 /PRNewswire/ -- The "Autonomous Driving Map Industry Report, 2024" report has been added to ResearchAndMarkets.com's offering.
  • );
    Application scenarios of intelligent driving map (high-speed autonomous driving of passenger cars, low-speed parking, autonomous human carrying, autonomous object carrying, etc.
  • 1 Status Quo of Policies, Standards and Regulations Concerning Autonomous Driving Map
    2.2 Classification of Autonomous Driving Maps: Navigation Map (SD Map)
    2.3 Classification of Autonomous Driving Maps: ADAS Map (SD Pro MAP)
    2.4 Classification of Autonomous Driving Maps: HD Map
    2.5 How Do Conventional Map Providers Make Layout Driven by Urban NOA?
  • 4.3 Intelligent Driving Map Application in Sub-scenarios: Low-speed Parking of Passenger Cars
    4.4 Intelligent Driving Map Application in Sub-scenarios: Autonomous Object Carrying
    4.5 Intelligent Driving Map Application in Sub-scenarios: Autonomous Human Carrying